Document |
Document Title |
WO/1998/003473A1 |
The present invention relates to novel compounds of general formula (I), pharmaceutical compositions containing them, a method of stimulating the release of growth hormone from the pituitary, a method for increasing the rate and extent o...
|
WO/1997/049667A1 |
Inhibitors of oleamide hydrolase, responsible for the hydrolysis of an endogenous sleep-inducing lipid (1, cis-9-octadecenamide) were designed and synthesized. The most potent inhibitors possess an electrophilic carbonyl group capable of...
|
WO/1997/047633A1 |
The present invention relates to rigid chiral ligands useful in making catalysts for asymmetric synthesis. More particularly, the present invention relates to new monodentate and bidentate cyclic chiral phosphine ligands which are formed...
|
WO/1997/044330A1 |
There is disclosed a process for the preparation of fluconazol which is a well-known antifungic agent, as well as pharmaceutically acceptable salts thereof, wherein a new compound having the formula (IV) in which R is H, benzyl, tripheny...
|
WO/1997/043251A1 |
Compounds of formula (I), wherein R' is hydrogen or alkyl; A is adamantyl or a mono-, bi- or tricyclic residue optionally unsaturated, a heterocyclic residue and/or substituted by hydroxy, alkanoyloxy, amino, aminoalkyl, halogen, alkyl, ...
|
WO/1997/040029A1 |
There are described compounds of formula (I*) wherein R1 is lower alkoxycarbonyl, R2 is secondary or tertiary lower alkyl or lower alkylthio-lower alkyl, R3 is phenyl that is unsubsituted or substituted by one or more lower alkoxy radica...
|
WO/1997/036480A1 |
Modified amino acid compounds useful in the delivery of active agents are provided. Methods of administration and preparation are provided as well.
|
WO/1997/033862A1 |
A compound of formula (I) wherein R is a) phenyl; phenyl (C1-C4 alkoxy); phenoxy; or benzyl; the phenyl ring of each substituent being optionally substituted with one or more of halogen, nitro, C1-C8 alkyl, C1-C8 alkoxy, C1-C8 haloalkyl,...
|
WO/1997/024316A1 |
The invention involves a procedure for synthesizing aryl hydrazine through reduction of a diazo derivative. The distinguishing feature of the method is that it involves at least the following step: c) bringing a diazo derivative into con...
|
WO/1997/023446A1 |
A process for the hydrocyanation of diolefins employing a catalyst comprising the combination of a zero-valent nickel compound and certain bidentate phosphorus compounds, and a process for isomerizing 2-alkyl-3-monoalkenenitrile to form ...
|
WO/1997/022579A1 |
A process for producing a hydrazide of formula (1.0) is disclosed. The process comprises reacting a hydrazone of formula (2.0) or (2.1), wherein said hydrazone is in toluene, with a mixture of Grignard reagents, wherein said Grignard rea...
|
WO/1997/021432A1 |
The therapeutical use of bicyclic derivatives and pharmaceutically acceptable salts thereof having general formula (I), wherein each of X1, X2, X3 and X4 is independently a carbon atom or a nitrogen atom, with n being 0 or 1; A is select...
|
WO/1997/016433A1 |
The present invention provides compounds which inhibit proteases, including cathepsin K, pharmaceutical compositions of such compounds, and methods for treating diseases of excessive bone loss or cartilage or matrix degradation, includin...
|
WO/1997/016177A1 |
A novel cathepsin K crystalline structure is identified. Also disclosed are methods of identifying inhibitors of this protease and methods of inhibiting cathepsin K using inhibitors with certain structural, physical and spatial character...
|
WO/1997/015280A1 |
The use of at least one NO synthase inhibitor as the active principle in a cosmetic composition for treating and/or preventing sensitive skin is disclosed. The use of at least one NO synthase inhibitor for preparing a pharmaceutical and ...
|
WO/1997/012851A1 |
A method for inhibiting the polymerization of vinyl compounds by using N-nitrosophenylhydroxylamine or salts thereof, wherein further use is made of either a copper salt or a combination of a metal dialkyldithiocarbamate with at least on...
|
WO/1997/007091A1 |
The invention concerns novel fluorobutenic acid hydrazides of formula (I) in which: Y stands for C=O, C=S or SO2; R1 stands for hydrogen or halogen; and R2 stands for alkyl, alkyl halide, alkoxyalkyl, alkylthioalkyl, cycloalkyl, alkenyl,...
|
WO/1997/002257A1 |
Compounds having structural formula (I) or (II), wherein R is C1-C6 alkoxy or C1-C6 alkyl; R1 is fluorenyl, thienyl, pyridyl or thiazolyl, unsubstituted or substituted by one or more substituents selected from C1-C4 alkoxy, C1-C4 alkyl, ...
|
WO/1996/041795A1 |
This invention relates to new benzamide derivatives having a vasopressin antagonistic activity, etc., and represented by general formula (I), wherein R1 is aryl optionally substituted with lower alkoxy, etc., R2 is lower alkyl, etc., R3 ...
|
WO/1996/036326A1 |
Nitric oxide has proved to mediate many important physiological processes. The nitric oxide donors of the present invention have a NONOate anion linked to an ortho-substituted aryl, a heteroaromatic substituent, a steroid, or a catechola...
|
WO/1996/033163A1 |
Chiral hydrazine derivatives of the formula (Ia), (Ib), (Ic) and (Id), wherein R1 and R2 are independently C1-C10 alkyl; R3 is H or R4 wherein R4 is a hydroxy protecting group; and Z is H, -CHO, -C(O)OC(CH3)3 or -C(O)OCH2C6H5; are disclo...
|
WO/1996/032382A1 |
Substituted 1-phenylpyrazole-3-carboxamides of formula (I) are disclosed for use as compounds having high affinity for human neurotensin receptors.
|
WO/1996/017824A2 |
Compounds and methods are provided for use in monosaccharide analysis. The present invention discloses hydrazino monosaccharide derivatives. Methods for preparing and using hydrazino monosaccharide derivatives for structural analysis of ...
|
WO/1996/017840A1 |
Compounds of formula (I) wherein Q is optionally substituted heterocyclyl; Z is optionally substituted hydroxy or mercapto; E is (i) CO--N(R2), (ii) CS--N(R2) or (iii) C(SR2) = N; W is O, N(R3), optionally substituted methylene or ethyle...
|
WO/1996/012482A1 |
This invention relates to a class of aminimides structurally characterized as an acyl nitrogen-nitrogen ylide such that the acyl moiety possesses the structural diversity element G, the quaternary nitrogen possesses structural diversity ...
|
WO/1996/011905A1 |
A fluorinated polyether compound represented by the following general formula (1): X-(Rf1)-(CF2)x-(CH2)y-{CHR-CH2}z1-Y1-Z1 or (1'): Z2-Y2-{CH2-CHR}z2-(CH2)y-(CF2)x-(Rf2)-(CF2)x-(CH2)y-{CHR-CH2
}z3-Y3-Z3, a lubricating oil, and a magnetic...
|
WO/1996/003982A1 |
Disclosed are compounds, compositions and methods for inhibiting interleukin-1 'beta' protease activity. The compounds, 'alpha'-substituted acetamides are of formula (A), wherein: R2 = H or alkyl; R3 = halo, O(CO)0-1aryl, OPOR4R5; (a), (...
|
WO/1996/003120A1 |
A class of novel indene-1-functional compounds is disclosed together with the use of such indene compounds for inhibiting sPLA2 mediated release of fatty acids for treatment of conditions such as septic shock. The compounds are indene-1-...
|
WO/1995/033710A1 |
Disclosed are carbamoyl carboxylic acid hydrazides (I) and their salts, wherein: R1 is optionally substitued alkyl, alkenyl, alkinyl, cycloalkyl, cycloalkenyl, aryl or heteroaryl or an optionally substituted non-aromatic carbo- or hetero...
|
WO/1995/032184A1 |
Aminimide- and oxazolone-based molecules, and arrays thereof, having at least two structural diversity elements are made via systematic modular production. A combinatorial library of aminimide- and oxazolone-based molecules is made via s...
|
WO/1995/032453A1 |
This subject invention relates to novel dihydrazide compounds of general formula (1), where B and C are the same or different and have general structure (I). A+ and A++ are activity regulating groups, and G- is a negatively charged ion u...
|
WO/1995/030682A1 |
A compound represented by general formula (I) or a pharmaceutically acceptable salt thereof, wherein R1 and R2 represent each OH, R1 being present at the 1- or 2-position while R2 being present at the 10- or 11-position, provided when R1...
|
WO/1995/024381A1 |
This invention relates to compounds of formula (I) which are useful as PDE IV inhibitors and for treating diseases related thereto.
|
WO/1995/022520A1 |
A compound of structure (I), wherein, when R8 = H: R1 = alkyl, cycloalkyl, arylalkyl, aryl; R2 = cycloalkyl, aryl, C3-C10 alkyl; X, Y = O, S(O)n, NH; Z = CH2OH, NHSO2R3, CHO, CO2R3, CONHR4R5, CN, COR6, H, halo, NHCN, NHCONR4R5, CONR4OR5,...
|
WO/1995/018972A1 |
A method for obtaining compounds having selected properties for a particular application by forming base modules having at least two structural diversity elements from the reaction of a first compound having at least one structural diver...
|
WO/1995/018623A1 |
Novel compounds and libraries of compounds based on nitrogen atoms that are joined together with spanner groups include "letters", i.e. functional groups, that are attached to the nitrogen atoms, to the spanner groups or to both the nitr...
|
WO/1995/018186A1 |
The design and synthesis of novel aminimide-derived molecular modules and the use of the modules in the construction of new molecules and fabricated materials is disclosed. The new molecules and fabricated materials are molecular recogni...
|
WO/1995/007269A1 |
The invention relates to retroviral protease inhibitors of the general formula (I): W-(A)n-B-(A*)m-V where W, A, B, A*, V, n and m are as defined herein, including related prodrugs of general formula (I) comprising a solubilising group w...
|
WO/1995/000472A1 |
The invention concerns acid derivatives of the formula (I): R1-CON(R2)-N(R3)CO-X1-Q-X2-G, and pharmaceutically acceptable metabolically labile esters or amides thereof, and pharmaceutically acceptable salts thereof; wherein R1 represents...
|
WO/1994/029267A1 |
Compounds of formula (I), in which A is an optionally substituted aryl group; A' is an optionally substituted aryl group; B is a carbonyl group or a methylene group which is substituted by optionally substituted hydroxy and an optional f...
|
WO/1994/017074A1 |
A process for preparing a compound of formula (I) or a phamaceutically-acceptable salt thereof, comprising: 1) reacting a compound of formula (III), in which R is a straight or branched chain alkyl having from one to four carbon atoms, w...
|
WO/1994/011334A1 |
Compounds of general formula (I) in which the index and the constituents have the meanings below: n: 0, 1, 2, 3 or 4; X: CHOCH3, CHCH3 or NOCH3; Y: O or NH; R1: nitro, cyano, halogen, alkyl, alkyl halide, alkoxy, alkoxy halide, alkylthio...
|
WO/1994/010148A1 |
The present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof wherein W is selected from optionally substituted pyridyl, naphthyl, and quinolyl; which inhibits lipoxygenase enzyme activity and l...
|
WO/1994/006280A1 |
Compositions and methods for treating a patient infected with a metazoan parasite by inhibiting the enzymatic action of the metazoan parasite protease. These compositions and methods have particular utility in the treatment of schistosom...
|
WO/1994/005643A1 |
This invention relates to novel neopentyl difluoroamino compounds which are useful as plasticizers and oxidizers in energetic formulations, such as propellants, explosives, and gasifiers. These neopentyl difluoroamino compounds can be pr...
|
WO/1994/005153A1 |
Herbicidal compositions and method of use involving effective amounts of substituted benzene compounds to control the growth of undesired vegetation.
|
WO/1994/001771A1 |
A universal standard chemical reagent for quantitative visual and spectrometric analysis of compounds having reactive functional groups, including mixtures and homologs of said compounds, said reagent comprising a compound of the general...
|
WO/1994/001102A1 |
The design and synthesis of novel aminimide-based molecular modules and the use of the modules in the construction of new molecules and fabricated materials is disclosed. The new molecules and fabricated materials are molecular recogniti...
|
WO/1993/023024A1 |
A method for the treatment of arrhythmia in human or non-human mammals, which method comprises the administration of an effective, non-toxic amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof and/or a pharm...
|
WO/1993/022273A1 |
Reaction of amine-containing substrates with hydrogen peroxide can suffer from certain problems, especially in the presence of transition metals. These problems include both in situ generation of impurities and particularly nitrosamines,...
|